The EFEMP1 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted disruption of the EFEMP1 gene, encoding the extracellular matrix glycoprotein fibulin-3. This polyclonal knockout model provides a heterogeneous pool of edited cells for studying fibulin-3 loss-of-function in a human cervical cancer background.
HeLa cells are derived from a HPV18-positive cervical adenocarcinoma and serve as a widely used epithelial model for cervical cancer research. Their transformed phenotype and well-characterized signaling pathways make them suitable for investigating tumor biology, cell adhesion, and migration.
Fibulin-3, encoded by EFEMP1, is a secreted glycoprotein that interacts with extracellular matrix components including collagen and fibronectin, and engages integrin receptors to regulate cell adhesion and migration. Fibulin-3 functions as a modulator of TGF-beta signaling, with evidence suggesting that it can suppress TGF-beta pathway activity. In HeLa cells, EFEMP1 expression is regulated by TGF-beta, hypoxia-inducible factors, and p53, and its loss alleviates suppression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), potentially altering pericellular proteolysis and integrin-mediated signaling downstream of TGF-beta.
In the HeLa cervical cancer context, EFEMP1 knockout eliminates fibulin-3, thereby disrupting extracellular matrix integrity and integrin-dependent adhesion. This perturbation is predicted to relieve fibulin-3-mediated suppression of TGF-beta signaling, enhancing downstream effectors such as MMPs and promoting epithelial-mesenchymal transition. Consequently, the knockout model may exhibit altered migratory and invasive behavior, making it a powerful tool for dissecting the tumor-suppressive roles of fibulin-3 and its interplay with the TGF-beta and integrin signaling networks.
This polyclonal EFEMP1 knockout HeLa cell population is ideally suited for functional studies of fibulin-3 in cancer biology, including tumor suppression, cell migration, and invasion assays. Researchers can employ western blotting and RT-qPCR to validate EFEMP1 disruption, while live-cell migration and Matrigel invasion assays, combined with cell adhesion and immunofluorescence analyses, enable detailed phenotypic characterization. Furthermore, the model supports senescence studies using senescence-associated beta-galactosidase staining, given fibulin-3??s emerging role in cellular senescence. For further information, please contact Ascent Research.
